Sentiment Analysis Scan — 2026-03-15
Scan mode: abbreviated watchlist sweep. Full analysis deferred due to context budget.
Methodology
Tracking narrative status (Inflection / Accelerating / Consensus / Fading), sentiment gap between expert and mainstream views, and catalyst proximity.
Macro Sentiment
- Fear/Greed: Elevated fear. "Peak war panic" predicted in 1-3 weeks by Alpine Macro strategist.
- Market mood: S&P 500 down only 3.6% since war began — described as "muted reaction" to a conflict threatening 20% of global oil supply. Gap between oil price severity and equity market complacency suggests either markets expect quick resolution or a delayed correction is coming.
- Contrarian signal: Jim Cramer says don't panic. History shows wars create buying opportunities within 3-6 months.
Watchlist Sentiment Scan
| Ticker | Narrative Status | Catalyst | Sentiment | Gap | Verdict |
|---|---|---|---|---|---|
| HIMS | Inflection | Novo Nordisk deal removes legal risk, FDA endorses model | Bullish surge +41% | 15% — market pricing deal revenue but undervaluing moat | Actionable — pullback entry |
| NBIS | Inflection | NVIDIA $2B investment, Rubin access | Bullish +26% | 20% — market treats as GPU reseller, but co-development deal = deeper | Actionable — support entry |
| OKLO | Accelerating | Meta prepayment, NRC tailwinds, KHNP partnership | Bullish | 10% — sector broadly bid but OKLO's specific catalysts under-covered | Watch for March 17 update |
| IREN | Accelerating | Microsoft deal, MSCI inclusion, 150K GPUs | Very Bullish | Low — consensus caught up. +580% YTD = crowded | Caution — late entry risk |
| AMPX | Inflection | First positive EBITDA, Nokia drone contract, defense demand | Early Bullish | 25% — still under-covered, defense angle not priced | Actionable — early position |
| TSLA | Mixed | Terafab announcement, Optimus Gen 3 production | Polarized | High — bulls see vertical integration, bears see $25B capex hole | Hold/research |
| NVDA | Consensus | Nemotron 3 Super, NBIS deal | Bullish consensus | Low — fully covered | Hold |
| NVO | Mixed | HIMS deal = distribution gain but compounding revenue loss | Neutral | Moderate | Hold |
| NET | Quiet | Strong Q4, waiting Q1 April 30 | Neutral-positive | Low | Hold |
| NFLX | Consensus | Defensive, ad-tier growth | Neutral | Low | Hold |
Reddit Sentiment Signals
Tier 1 Expert Subs (Early Signal)
- r/nuclear: TerraPower NRC approval generating expert excitement. Epstein controversy creating noise but experts view it as non-material to the tech.
- r/energy: Dominated by Iran war / oil supply disruption. 766-upvote post on solar panel longevity. Nuclear SMR founders getting scrutiny.
- r/Semiconductors: Tesla Terafab announcement generating significant discussion (163 upvotes, 85 comments). Skepticism about timeline.
- r/electricvehicles: Chinese EV dominance narrative strengthening. New Chevy Bolt charging speed praised. Honda/VW/Porsche struggling.
Tier 2 Investing Subs
- r/ClaudeAI: Claude turning 3, 1M context window for MAX plans, doubled off-peak usage. High engagement on Claude Code capabilities.
- r/LocalLLaMA: Nvidia Nemotron 3 Super getting significant attention (388 upvotes). Qwen3.5 models performing well locally.
- r/MachineLearning: arXiv separating from Cornell (347 upvotes) — institutional shift.
Signal Flow Detection
- Tesla Terafab: Appearing in r/Semiconductors but NOT yet in mainstream investing subs = early signal.
- AMPX defense angle: r/drones discussing crop monitoring and commercial use, not yet connecting to AMPX battery demand = pre-signal.
- Nemotron 3 Super: r/LocalLLaMA enthusiastic but r/stocks hasn't picked it up as an NVDA catalyst yet.
Key Divergences
- Oil/equity disconnect: Oil up 40-70%, equities down only 3%. Either oil overshot or equities haven't caught up. Historical precedent suggests equities eventually reprice.
- Nuclear sentiment: Expert subs very constructive on NRC progress and TerraPower permit. Mainstream media focused on Epstein angle. The technology story is under-covered.
- HIMS transformation: Market priced the +41% pop but hasn't fully valued the strategic shift from compounding shop to authorized Novo distributor with FDA endorsement.
Generated: 2026-03-15 | Scan mode — abbreviated analysis based on available data